Stroke and atherothrombosis

An update on the role of antiplatelet therapy

Andrei Alexandrov, Peter Alagona

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Atherothrombosis is responsible for most acute ischemic manifestations of atherosclerotic disease, including stroke. Individuals with evidence of atherothrombotic disease in one vascular bed have a significant risk of recurrence and show increased vulnerability over time for other manifestations elsewhere in the vasculature. Ischemic event rates for asymptomatic patients with multiple atherothrombotic risk factors appear to be similar to those in patients with documented cardiovascular disease. For example, diabetes mellitus and obesity are found at alarmingly high rates in patients with prior cardiovascular events, including stroke or transient ischemic attacks. Antiplatelet therapy is a key component of atherothrombotic event prevention. The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) study showed that while dual antiplatelet therapy with aspirin and clopidogrel may not play a role in primary prevention, post hoc analysis alluded to the possibility of benefit for dual antiplatelet therapy in certain populations of stroke patients. We examined current recommendations for the prevention of atherothrombotic events, focusing on the role of oral antiplatelet agents in patients with ischemic stroke.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalInternational Journal of Stroke
Volume3
Issue number3
DOIs
StatePublished - Aug 12 2008

Fingerprint

clopidogrel
Stroke
Therapeutics
Platelet Aggregation Inhibitors
Transient Ischemic Attack
Primary Prevention
Aspirin
Blood Vessels
Diabetes Mellitus
Cardiovascular Diseases
Obesity
Recurrence
Population

All Science Journal Classification (ASJC) codes

  • Neurology

Cite this

Stroke and atherothrombosis : An update on the role of antiplatelet therapy. / Alexandrov, Andrei; Alagona, Peter.

In: International Journal of Stroke, Vol. 3, No. 3, 12.08.2008, p. 175-181.

Research output: Contribution to journalReview article

@article{f5c5ab78562548a29bdde485c781856b,
title = "Stroke and atherothrombosis: An update on the role of antiplatelet therapy",
abstract = "Atherothrombosis is responsible for most acute ischemic manifestations of atherosclerotic disease, including stroke. Individuals with evidence of atherothrombotic disease in one vascular bed have a significant risk of recurrence and show increased vulnerability over time for other manifestations elsewhere in the vasculature. Ischemic event rates for asymptomatic patients with multiple atherothrombotic risk factors appear to be similar to those in patients with documented cardiovascular disease. For example, diabetes mellitus and obesity are found at alarmingly high rates in patients with prior cardiovascular events, including stroke or transient ischemic attacks. Antiplatelet therapy is a key component of atherothrombotic event prevention. The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) study showed that while dual antiplatelet therapy with aspirin and clopidogrel may not play a role in primary prevention, post hoc analysis alluded to the possibility of benefit for dual antiplatelet therapy in certain populations of stroke patients. We examined current recommendations for the prevention of atherothrombotic events, focusing on the role of oral antiplatelet agents in patients with ischemic stroke.",
author = "Andrei Alexandrov and Peter Alagona",
year = "2008",
month = "8",
day = "12",
doi = "10.1111/j.1747-4949.2008.00198.x",
language = "English (US)",
volume = "3",
pages = "175--181",
journal = "International Journal of Stroke",
issn = "1747-4930",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Stroke and atherothrombosis

T2 - An update on the role of antiplatelet therapy

AU - Alexandrov, Andrei

AU - Alagona, Peter

PY - 2008/8/12

Y1 - 2008/8/12

N2 - Atherothrombosis is responsible for most acute ischemic manifestations of atherosclerotic disease, including stroke. Individuals with evidence of atherothrombotic disease in one vascular bed have a significant risk of recurrence and show increased vulnerability over time for other manifestations elsewhere in the vasculature. Ischemic event rates for asymptomatic patients with multiple atherothrombotic risk factors appear to be similar to those in patients with documented cardiovascular disease. For example, diabetes mellitus and obesity are found at alarmingly high rates in patients with prior cardiovascular events, including stroke or transient ischemic attacks. Antiplatelet therapy is a key component of atherothrombotic event prevention. The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) study showed that while dual antiplatelet therapy with aspirin and clopidogrel may not play a role in primary prevention, post hoc analysis alluded to the possibility of benefit for dual antiplatelet therapy in certain populations of stroke patients. We examined current recommendations for the prevention of atherothrombotic events, focusing on the role of oral antiplatelet agents in patients with ischemic stroke.

AB - Atherothrombosis is responsible for most acute ischemic manifestations of atherosclerotic disease, including stroke. Individuals with evidence of atherothrombotic disease in one vascular bed have a significant risk of recurrence and show increased vulnerability over time for other manifestations elsewhere in the vasculature. Ischemic event rates for asymptomatic patients with multiple atherothrombotic risk factors appear to be similar to those in patients with documented cardiovascular disease. For example, diabetes mellitus and obesity are found at alarmingly high rates in patients with prior cardiovascular events, including stroke or transient ischemic attacks. Antiplatelet therapy is a key component of atherothrombotic event prevention. The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) study showed that while dual antiplatelet therapy with aspirin and clopidogrel may not play a role in primary prevention, post hoc analysis alluded to the possibility of benefit for dual antiplatelet therapy in certain populations of stroke patients. We examined current recommendations for the prevention of atherothrombotic events, focusing on the role of oral antiplatelet agents in patients with ischemic stroke.

UR - http://www.scopus.com/inward/record.url?scp=48849096211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849096211&partnerID=8YFLogxK

U2 - 10.1111/j.1747-4949.2008.00198.x

DO - 10.1111/j.1747-4949.2008.00198.x

M3 - Review article

VL - 3

SP - 175

EP - 181

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

IS - 3

ER -